Yun Ji
About Yun Ji
Yun Ji serves as the Director of Research and Translational Sciences at Brii Biosciences, where she has worked since 2020. She holds a Ph.D. in Neuroscience from Iowa State University and has a strong publication record in T cell-based immunotherapy.
Work at Brii Biosciences
Yun Ji has served as the Director of Research and Translational Sciences at Brii Biosciences since 2020. In this role, she focuses on advancing research initiatives in immunotherapy, particularly in the area of T cell-based therapies. Her work contributes to the company's efforts in developing innovative solutions for immuno-oncology. Brii Biosciences is located in Gaithersburg, Maryland, and is dedicated to addressing unmet medical needs through scientific advancements.
Education and Expertise
Yun Ji holds a Bachelor of Science degree in Biology from Fudan University, which she completed from 1991 to 1996. She then pursued her Ph.D. in Neuroscience, with a focus on Molecular and Cellular Biology, at Iowa State University from 1999 to 2004. Her academic background has equipped her with a strong foundation in biological sciences, which she applies to her research in T cell differentiation and immunotherapy.
Background
Before her tenure at Brii Biosciences, Yun Ji worked as a Postdoctoral Fellow at Georgetown University from 2004 to 2007. This position allowed her to deepen her research experience and contribute to the field of immunology. Her background includes extensive training in T cell-based immunotherapy and a focus on T cell exhaustion, which are critical areas in the development of cancer treatments.
Achievements
Yun Ji has an exceptional publication record in the fields of T cell-based immunotherapy and T cell differentiation. She has successfully developed and implemented immunotherapy strategies that have advanced research and development in immuno-oncology. Additionally, she has demonstrated skills in building and leading multi-disciplinary teams, as well as managing collaborations with both internal and external stakeholders.